Abstract:Objective To explore the clinical value of fecal calprotectin and myeloperoxidase in evaluation of ulcerative colitis (UC) activity.Methods Specimens of serum and feces over the same period were collected from 49 ulcerative colitis (UC) patients (32 male and 17 female)and 35 healthy controls (23 male and 12 female).ELISA was used to measure the concentration of calprotectin and myeloperoxidase in feces.The clinical information (including Mayo clinic activity index.Baron endoscopic score) of UC patients were collected.All patients were divided into active and inactive group by Mayo clinic activity index,the active group was further divided into three subgroups,the mild group,the moderate group and the severe group.Fecal calprotectin and myeloperoxidase,serum ESR and CRP were compared among different groups,receiver operating curve (ROC) were obtained to evaluate the diagnostic efficacy of the UC activity.Results The fecal calprotectin concentration was significantly higher in active UC group than that in inactive UC group [6000.0 (3050.8,8759.5) vs.336.8 (227.5,1731.0),Z =-3.357,P =0.001],the same to inactive UC group and the controls[336.8(227.5,1731.0) vs.29.0(21.3,48.8),Z =-5.607,P =0.001].The fecal myeloperoxidase concentration of the active UC group was significantly higher than that of the inactive UC group[1231.2(757.9,1481.1) vs.603.6(265.2,819.4),Z =-3.658,P =0.001],but there was no significant difference between the inactive UC group and the controls [603.6 (265.2,819.4) vs.453.5(140.8,750.2),Z =-1.033,P =0.302].There was no significant difference of fecal calprotectin levels among different active subgroups.Fecal myeloperoxidase concentration between the mild activity group and the moderate activity group was significant [667.3 (467.5,1000.4) vs.1259.6 (1213.3,1932.8),Z =-2.475,P =0.005],but there was no significant difference between the moderate activity group and the severe activity group [1259.6 (1213.3,1932.8) vs.1239.0 (793.9,1403.0),Z =-1.350,P =0.193].The four biomarkers were all positively correlated with the endoscopic score and Mayo clinic activity index of UC.Conclusions Considered as noninvasive biomarkers of disease activity fecal calprotectin and myeloperoxidase is similar to ESR and serum CRP.Fecal calprotectin is superior to myeloperoxidase in differentiating the inactive UC group from the controls.(Chin J Lab Med,2013,36:348-351)

Clinical value of indices of clinical monitoring disease activity of inflammatory bowel disease

IDDF2019-ABS-0186 Correlation Between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

Serum and Feces Myeloperoxidase Determination for Auxiliary Diagnosis and Monitoring of Disease Activity in Patients with Ulcerative Colitis

Quantitative Proteomic Analysis Reveals the Deregulation of Nicotinamide Adenine Dinucleotide Metabolism and CD38 in Inflammatory Bowel Disease.

Application of Fecal Calprotectin and Myeloperoxidase in Evaluation of Disease Activity of Ulcerative Colitis

Correlation between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease

Predictive value of serum markers for mucosal healing in patients with inflammatory bowel disease

Combined Use of Fecal Biomarkers in Inflammatory Bowel Diseases: Oncostatin M and Calprotectin

Gene Expression Alterations in Inflamed and Unaffected Colon Mucosa from Patients with Mild Inflammatory Bowel Disease.

Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic Crohn's disease

The Correlation Between Endotoxin, D-Lactate and Diamine Oxidase with Endoscopic Activity in Inflammatory Bowel Disease

The role of new inflammatory indices in the prediction of endoscopic and histological activity in inflammatory bowel disease patients

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Serum oncostatin M is a potential biomarker of disease activity and infliximab response in inflammatory bowel disease measured by chemiluminescence immunoassay

Mucosal Genes Expression in Inflammatory Bowel Disease Patients: New Insights

Fecal and serum granulocyte protein levels in inflammatory bowel disease and irritable bowel syndrome and their relation to disease activity

Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease

Neutrophil and Eosinophil Granule Proteins As Potential Biomarkers of Assessing Disease Activity and Severity in Patients with Ulcerative Colitis.

Oxidative stress-related biomarkers as promising indicators of inflammatory bowel disease activity: A systematic review and meta-analysis

Assessment of IBD disease activity by Interleukin-6 and serum amyloid A in relation with fecal calprotectin and endoscopic indices